ASHLEY MCKILLOP: Open Payments
NPI 1851885446 · LAKEWOOD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,160 in 152 payments from 19 companies in 2025. Trend: 2023 $3,223 · 2024 $3,931 · 2025 $3,160
Food & beverage: $3,160
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 44 | $928 |
| Janssen Biotech, Inc. | 20 | $490 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 19 | $336 |
| Madrigal Pharmaceuticals | 9 | $323 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $143 |
| Gilead Sciences, Inc. | 6 | $125 |
| Phathom Pharmaceuticals, Inc. | 9 | $121 |
| Lilly USA, LLC | 8 | $121 |
| GENZYME CORPORATION | 5 | $116 |
| Regeneron Healthcare Solutions, Inc. | 4 | $91 |
Products named: TREMFYA, SKYRIZI, RINVOQ, XIFAXAN, REZDIFFRA, DUPIXENT, LINZESS, VOQUEZNA.
Industry payments across CO — which companies pay providers there.
